Dr Robert W Theakston, MD | |
211 Greenhill Blvd Nw, Fort Payne, AL 35967-3755 | |
(256) 845-9355 | |
Not Available |
Full Name | Dr Robert W Theakston |
---|---|
Gender | Male |
Speciality | General Practice |
Experience | 28 Years |
Location | 211 Greenhill Blvd Nw, Fort Payne, Alabama |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255374492 | NPI | - | NPPES |
009932309 | Medicaid | AL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 19991 (Alabama) | Secondary |
208D00000X | General Practice | 19991 (Alabama) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Dekalb Regional Medical Center | Fort payne, AL | Hospital |
Entity Name | Northside Medical, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1205089372 PECOS PAC ID: 7517029937 Enrollment ID: O20081218000752 |
News Archive
Everyone knows that stem cells are controversial. Many people know that stem cells can grow into virtually any cell type found in the body, from a red blood cell to a muscle cell to a brain cell. But no one really knows why stem cells continue to divide and renew themselves long after the point where other cells stop dividing.
Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
› Verified 1 days ago
Entity Name | Em Transform, Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1285417154 PECOS PAC ID: 6507216454 Enrollment ID: O20231219002105 |
News Archive
Everyone knows that stem cells are controversial. Many people know that stem cells can grow into virtually any cell type found in the body, from a red blood cell to a muscle cell to a brain cell. But no one really knows why stem cells continue to divide and renew themselves long after the point where other cells stop dividing.
Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Robert W Theakston, MD 211 Greenhill Blvd Nw, Fort Payne, AL 35967-3755 Ph: (256) 845-9355 | Dr Robert W Theakston, MD 211 Greenhill Blvd Nw, Fort Payne, AL 35967-3755 Ph: (256) 845-9355 |
News Archive
Everyone knows that stem cells are controversial. Many people know that stem cells can grow into virtually any cell type found in the body, from a red blood cell to a muscle cell to a brain cell. But no one really knows why stem cells continue to divide and renew themselves long after the point where other cells stop dividing.
Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
› Verified 1 days ago